

February 5, 2018

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Monday, February 5, 2018

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board Meeting of the Company held on Monday, February 5, 2018, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2017. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated February 5, 2018 are enclosed herewith.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited


Pratap Rudra
Company Secretary & Legal Counsel



CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Statement of unaudited results for the quarter and nine months ended 31 December 2017

Sl No.	Particulars	Rs in lakhs				
		3 months ended 31/12/2017 (Unaudited)	3 months ended 30/09/2017 (Unaudited)	3 months ended 31/12/2016 (Unaudited)	9 months ended 31/12/2017 (Unaudited)	9 months ended 31/12/2016 (Unaudited)
1	Revenue					
	a) Revenue from operations	12,853.86	16,425.83	15,150.22	42,126.27	43,177.37
	b) Other income	275.97	249.57	989.77	990.94	1,339.74
	Total revenue	13,129.83	16,675.40	16,139.99	43,117.21	44,517.11
2	Expenses					
	(a) Cost of materials consumed	778.78	312.40	244.49	1,638.94	870.04
	(b) Purchase of stock-in-trade	7,326.39	4,778.19	3,561.85	17,948.54	11,394.42
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4,260.83)	254.76	893.09	(5,883.26)	1,319.11
	(d) Excise duty	-	-	121.61	98.50	378.13
	(e) Employee benefits expense	3,711.65	3,640.19	3,774.48	10,845.72	12,551.07
	(f) Depreciation and amortisation expense	373.01	374.85	401.92	1,118.66	1,215.10
	(g) Selling, marketing and distribution expense	2,456.81	1,526.49	1,861.29	5,169.21	4,564.88
	(h) Other expenses	3,925.63	2,348.84	3,181.04	9,206.54	8,475.07
	(i) Finance cost	-	-	-	-	-
	Total expenses	14,311.44	13,235.72	14,039.77	40,142.85	40,767.82
3	(Loss)/ Profit before exceptional and extraordinary items and tax (1-2)	(1,181.61)	3,439.68	2,100.22	2,974.36	3,749.29
4	Exceptional items	-	-	-	-	-
5	(Loss)/ Profit before extraordinary items and tax (3+4)	(1,181.61)	3,439.68	2,100.22	2,974.36	3,749.29
6	Extraordinary items	-	-	-	-	-
7	(Loss)/ Profit before tax (5+6)	(1,181.61)	3,439.68	2,100.22	2,974.36	3,749.29
8	Tax expense					
	- Current tax	(146.39)	698.77	479.18	704.99	787.85
	- Deferred tax	-	2.43	-	-	-
	Total tax expense	(146.39)	701.20	479.18	704.99	787.85
9	(Loss)/ Profit for the period (7-8)	(1,035.22)	2,738.48	1,621.04	2,269.37	2,961.44
10	Other comprehensive income, net of income tax					
	A. Items that will not be reclassified to profit or loss	243.27	(9.43)	(58.59)	282.60	(213.13)
	B. Items that will be reclassified to profit or loss	-	-	-	-	-
	Total other comprehensive income, net of income tax	243.27	(9.43)	(58.59)	282.60	(213.13)
	Total comprehensive income for the period (9+10)	(791.95)	2,729.05	1,562.45	2,551.97	2,748.31
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00	500.00
12	Earnings per equity share of Rs 2/- each (basic and diluted)	(4.14)	10.95	6.48	9.08	11.85



AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of unaudited results for the quarter and nine months ended 31 December 2017

Notes:

- 1 The above statement of results has been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 5 February 2018. The statutory auditors of the Company have carried out a limited review of this statement of results for the quarter ended 31 December 2017.
- 2 This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1 April 2017, the Company has for the first time adopted Ind AS with a transition date of 1 April 2016.
- 3 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 4 As previously disclosed, by way of a letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 5 The Statement does not include Ind AS compliant statement of results for the previous year ended 31 March 2017 as the same is not mandatory as per SEBI's circular dated 5 July 2016.
- 6 Previous period's figures have been regrouped to conform with the current period's presentation for the purpose of comparability.
- 7 The reconciliation of net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:

Particulars	3 months ended 31/12/2016	9 months ended 31/12/2016
(a) Net Profit as per previous GAAP (Indian GAAP)	1,596.29	2,731.76
Add/ (less): Adjustment for Ind AS		
Impact on provision of expected credit loss	(33.27)	(27.59)
Reversal of rent equalisation reserve	6.33	18.98
Reclassification of net actuarial (gain)/loss on defined benefit plan to other comprehensive income	58.59	213.13
Impact of Employee stock compensation plan	(19.40)	(18.57)
Others*	12.50	43.75
(b) Net profit after tax as per Ind AS	1,621.04	2,961.44
(c) Other comprehensive income net of income tax:		
Actuarial loss on defined benefit plan	(58.59)	(213.13)
(d) Total comprehensive income under Ind AS (b+c)	1,562.45	2,748.31

* Others mainly include adjustments on account of discounting of non-current security deposits, employee loans, fair value adjustment on equity investments etc.

**By Order of the Board of Directors
For AstraZeneca Pharma India Limited**



**Rajesh Marwaha
Chief Financial Officer & Director**

**Place: Bengaluru
Date: February 05, 2018**



Price Waterhouse & Co Chartered Accountants LLP

The Board of Directors
M/s. AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bengaluru 560045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended December 31, 2017 which are included in the accompanying 'Statement of unaudited results for the quarter and nine months ended December 31, 2017' together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") and SEBI Circular dated July 5, 2016, which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Further, the Management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company's opening unaudited Balance Sheet as at April 01, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 and SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road
Ulsoor, Bangalore-560 008
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026/E-300009 (ICAI registration number before conversion was 304026E)

Price Waterhouse & Co Chartered Accountants LLP

5. We draw attention to the following matters:

- a. Note 2 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2017 with a transition date of April 01, 2016, and accordingly, the Statement has been prepared by the Company's Management in compliance with Ind AS.
- b. The financial results of the Company for the nine months ended December 2016 includes financial results for the quarter ended June 30, 2016 which was reviewed by another firm of chartered accountants who, vide their report dated August 09, 2016, expressed an unmodified opinion on those financial results.

Our conclusion is not qualified in respect of these matters.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/ E-300009



Pradip Kanakia
Partner
Membership Number: 039985

Bangalore
February 05, 2018